Key terms
About MOR
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MOR news
Mar 27
1:57pm ET
MorphoSys AG Reports Major Shareholding Changes
Mar 26
11:57am ET
MorphoSys AG Reports Major Shareholding Change
Mar 25
11:57am ET
MorphoSys AG Reports Major Stake Change
Mar 22
11:57am ET
MorphoSys AG Reports Major Voting Rights Change
Mar 22
7:27am ET
MorphoSys Set for Novartis Takeover Post-U.S. Clearance
Mar 21
12:27pm ET
MorphoSys AG Announces Major Voting Rights Changes
Mar 20
4:57pm ET
MorphoSys’ Milestone Year Paves Way for Growth
Mar 20
12:27pm ET
MorphoSys AG Announces Shift in Shareholding
Mar 19
11:57am ET
MorphoSys AG Reports Major Voting Rights Change
Mar 18
12:27pm ET
MorphoSys AG Witnesses Major Voting Rights Shift
Mar 14
3:22pm ET
MorphoSys downgraded to Equal Weight from Overweight at Wells Fargo
Mar 14
11:05am ET
Morphosys Ag (MOR) Receives a Hold from JMP Securities
Mar 13
2:19pm ET
Morphosys Ag (ADR) options imply 3.4% move in share price post-earnings
Feb 15
11:45am ET
Morphosys Ag (ADR) call volume above normal and directionally bullish
Feb 08
11:40am ET
Biotech Alert: Searches spiking for these stocks today
Feb 08
4:37am ET
MorphoSys downgraded to Neutral from Buy at UBS
Feb 07
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 06
3:10pm ET
MorphoSys downgraded to Market Perform from Outperform at JMP Securities
Feb 06
1:48pm ET
MorphoSys tells Bloomberg STAT story ‘factually wrong’
Feb 06
1:46pm ET
JMP Securities downgrades Morphosys Ag (MOR) to a Hold
Feb 06
11:52am ET
Novartis will ‘walk away from’ deal to buy MorphoSys, STAT’s Feuerstein says
Feb 06
5:17am ET
M & A News: Novartis (NYSE:NVS) Acquires MorphoSys in $2.9B Deal
Feb 06
5:14am ET
MorphoSys upgraded to Neutral from Sell at Citi
Feb 05
4:59pm ET
Novartis to acquire MorphoSys for EUR 68 per share, or aggregate of EUR 2.7B
Feb 05
4:51pm ET
Incyte pays MorphoSys $25M for commercialization rights to Monjuvi
Feb 05
1:47pm ET
Cytokinetics weakness a buying opportunity, says Truist
Feb 05
1:20pm ET
Analysts Conflicted on These Healthcare Names: Cencora (COR) and Morphosys Ag (MOR)
Feb 05
1:11pm ET
MorphoSys could fetch $3B-$4B in a takeout, says Wells Fargo
Feb 05
10:20am ET
MorphoSys trading resumes, shares up 20% after Reuters report
Feb 05
10:20am ET
Morphosys Ag (ADR) trading resumes
Feb 05
10:20am ET
Novartis in lead to acquire MorphoSys, Reuters says
No recent news articles are available for MOR
No recent press releases are available for MOR
MOR Financials
Key terms
Ad Feedback
MOR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MOR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range